X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor
Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome
Guest speakers include thought leaders with expertise in the research and
treatment of rare immunodeficiencies
Webcast to take place following ASH Annual Meeting on
The event will feature presentations from X4 senior management and the following thought leaders, experts in the research and treatment of rare immunodeficiencies:
Neal Sondheimer , M.D., Ph.D., clinical and research geneticist at theUniversity of Toronto and Head of Metabolic Medicine atSickKids Hospital . His clinical work focuses on inherited metabolic disorders, while his research focuses on rare disease discovery and the impact of sequence variation in the mitochondrial genome on disease presentation.Teresa Tarrant , M.D., Associate Professor of Medicine, Rheumatology, and Immunology at theDuke University School of Medicine , where she focuses on understanding why and how autoimmunity and immune deficiency disorders develop. A practicing clinician, her research investigates immune targets that may either impact the development of immune disease or help identify new therapies for patients.
Webcast Details
X4 Virtual Seminar “Understanding Primary Immunodeficiencies”
Date:
Time:
Link to webcast
A live webcast will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com. Following the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days. Participants may also access the audio portion of the presentation by dialing (866) 721-7655 in the US, or (409) 216-0009 internationally, citing the following conference ID: 6995899.
About
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development and therapeutic potential of mavorixafor; X4’s potential growth and evolution; and the advancement of X4’s pipeline. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development; the risk that trials and studies may be delayed, including, but not limited to, as a result of the effects of the ongoing COVID-19 pandemic or delayed patient enrollment, and may not have satisfactory outcomes; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates; risks related to X4’s ability to raise additional capital and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 4, 2021, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.
Contacts:
VP, Investor Relations & Corporate Communications
glenn.schulman@x4pharma.com
(203) 494-7411
Managing Director,
daniel@lifesciadvisors.com
(617) 430-7576
Senior Account Executive,
mroucomolina@lifescicomms.com
Source: X4 Pharmaceuticals